Chemical patent

Chemical patent claims often use generic, Markush structures contained within them, named after the inventor Eugene Markush who won a lawsuit in the US in 1925 to allow such structures to be used in patent claims.

In the United States, patents on pharmaceuticals were considered unethical by the medical profession during most of the nineteenth-century.

There are several reasons for this peculiarity:[3][4][5] A 2021 analysis[7] of the most valuable US pharmaceutical patents published in the Orange Book between 2000 and 2018 showed that ca.

For litigated patents it takes approximately five office actions before allowance.

The main reason for invalidating these weak follow-up patents in courts is obviousness in view of the prior art, which was not considered by the examiner.